Next generation of cancer immunotherapy calls for combination by Cappello, Paola & Novelli, Francesco
19www.impactjournals.com/oncoscience Oncoscience
www.impactjournals.com/oncoscience/ Oncoscience, Vol. 4(3-4), March 2017
Next generation of cancer immunotherapy calls for combination
Paola Cappello and Francesco Novelli
Pancreatic ductal adenocarcinoma (PDA) is a 
lethal cancer resistant to chemotherapy and radiation 
therapy, thus requiring novel therapeutic options. 
Although immunotherapy has been widely explored 
for cancer treatment, pancreatic cancer seems to be not 
suitable for this approach as it is considered an “immune 
privileged site”. This is due to an immunosuppressive 
environment or to a low rate of mutations that generate 
neo-antigens able to activate anti-tumor T cells. However, 
our data demonstrate the presence of antigen-specific 
T cells in PDA, which recognize the tumor associated 
antigen (TAA) alpha-enolase (ENO1) [1], and could be 
challenged and expanded by a vaccine approach. This 
hypothesis was verified using a DNA vaccine coding for 
ENO1 in a genetically engineered mouse model (GEM) 
that spontaneously develops PDA. ENO1-vaccinated mice 
showed prolonged survival associated with the induction 
of specific antibodies to ENO1 that activate complement-
dependent cytotoxity (CDC); the decrease in tumor 
infiltration by T regulatory cells and myeloid-derived 
suppressor cells (MDSC); as well as the concomitant 
increase in tumor infiltrating T cells [2] re-localized into 
tertiary lymphoid tissue, reminiscent of a germinative 
center [3]. In addition to the induction of CDC, anti-
ENO1 antibodies are also responsible for some other 
effects; firstly, the inhibition of migration and invasion of 
PDA cells, as demonstrated in vitro and in vivo [4], and 
secondly, the decreased infiltration of MDSC. Indeed, we 
observed that MDSC express high surface levels of ENO1 
when stimulated by inflammatory stimuli, and anti-ENO1 
antibodies were able to block the interaction of MDSC 
with endothelial cells, limiting their invasion into the 
tumor [5].
The goal of immunotherapy is to enhance and direct 
the body’s immune system into recognizing tumor-specific 
antigens and thus mount an attack against the disease. In 
this light, the induction of a curative, long-lasting ENO1-
specific humoral and cellular anti-tumor responses, such 
as that directed against other antigens, relies on the 
combination with adjuvants acting as immune-stimulatory 
agents (e.g. CD40) or limiting immunosuppression 
(immune check-point inhibitors, myeloid suppressor cell 
depletion). The recognition of tumor cells by the immune 
system begins with the release of TAAs by dying tumor 
cells, subsequently taken up from resident macrophages or 
dendritic cells (collectively called antigen-presenting cells, 
APC), which process them via membrane-bound vesicles 
into smaller peptides. These peptides are subsequently 
associated with the major histocompatibility complex 
(MHC) class II molecules, and presented to CD4 T cells, 
along with MHC class I molecules, and cross-presented to 
CD8 T cells. CD4 T cell activation is mandatory for both 
B cell activation and production of antibodies, as well as 
for cytotoxic T lymphocyte generation and maintenance. 
In both orthotopic and GEM mouse models of PDA, 
we recently demonstrated that genetic or pharmacological 
inhibition of PI3Kγ limits myeloid suppressor cell 
infiltration, skews macrophage activation to the anti-
tumoral function and delays tumor growth and metastasis 
(particularly in combination with chemotherapy) by 
increasing the number of T cells that infiltrate the tumor 
[6]. This observation gives rise to the promising idea 
of targeting myeloid suppressor cells to limit tumor 
progression, even if the eventual recurrence could be 
specifically counteracted with the induction of the adaptive 
anti-tumor immune response achievable by vaccines. Other 
potential approaches of targeting myeloid cells in PDA 
have been shown by targeting CD40 or colony stimulating 
factor (CSF)1/CSF1 receptor (R). Anti-CD40 agonists 
redirect tumor-infiltrating monocytes/macrophages to 
induce degradation of fibrosis via metalloproteases, 
without T cell involvement [7]. CSF1/CSF1R blockade 
has been demonstrated to skew infiltrating macrophages 
from a more suppressive alternative phenotype, to an anti-
tumoral phenotype, with the consequent activation of T 
cells, thus proving beneficial in the combination with PD1 
or CTLA4 treatment [8].
All these approaches are promising for their 
combination with active immunotherapy. They have 
already shown clinical potential in combination with 
chemotherapy, but with vaccines have to be explored yet. 
There is an urgent need in cancer to avoid recurrence and 
metastasis in general and, therefore, active immunization 
against TAAs represents the only effective chance with 
low side effects. However, pre-clinical and clinical studies 
must elucidate the right timing, doses and administration 
modes for these candidate combinations to obtain the best 
benefits.
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